RTS Life Science Announces the Availability of New Sample Management Technical Paper
News May 14, 2008
RTS Life Science has announces the availability of its new Sample Management and Replication technical paper. The informative new poster is entitled, “A New Paradigm in Sample Library Management and Replication,” and discusses RTS’ innovative sample management solution Libradexx. The poster is now available free of charge in downloadable pdf format via www.rtslifescience.com or via e-mail on firstname.lastname@example.org.
Finding a solution which is suitable for all library sizes, manages the regeneration and replication process and incorporates the ability to report on results, while at the same time saving money, are just some of the challenges sample management and HTS professionals face when implementing a storage management system. This poster highlights RTS LibradexxTM, an integrated sample library management solution which allows plate management and data tracking to become ‘run of the mill’, freeing users to focus on the real challenges of sample management and HTS. RTS Libradexx supports both manual and automated storage solutions and is suitable for all library sizes.
The new technical poster was presented for the first time at SBS Annual Conference and Exhibition in April and is written by Chris Walsh, Julio Maher, Philip Cummings, David Harding and Claire Ridgway of RTS Life Science. This detailed poster discusses how RTS has partnered with a major pharmaceutical company to challenge the current accepted models for compound management and presents an overview of the outcome of this process. In particular, the poster details the increasing use of the Labcyte Echo 550/555 liquid handler by Sample Management and HTS professionals to perform very low liquid transfers.
With 25 years of experience delivering automation solutions, RTS Life Science is a major supplier of large scale sample storage and testing within the laboratory environment. Its market encompasses drug discovery applications within pharmaceutical and biotechnology companies, covering medical research, clinical trials and manufacturing applications.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE